NCT00116922|CompletedPhase 3DMC
A Lifestyle and Combination Medication Therapy Diabetes Prevention Study
CAnadian Normoglycemia Outcomes Evaluation Study
Loading search results
Sponsor study identifier
interventional
207
1 country
2
Study Start
June 2004
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
January 2010
Actual (reported)Study Completion
January 2010
Actual (reported)It is now well established that the 21st century will be characterized by a global epidemic of Type 2 diabetes. The principal aim of the CANOE study is to determine whether individuals with the pre-diabetes condition impaired glucose tolerance can be prevented from progressing to diabetes with a healthy living lifestyle intervention and an insulin sensitizing medication. Individuals who have impaired glucose tolerance (IGT) determined during an oral glucose tolerance test will be eligible to participate in this study. All participants will receive a lifestyle dietary and exercise intervention program. Half of the participants will be randomly assigned to an insulin sensitizing medication (rosiglitazone/metformin) which is commonly used to treat Type 2 diabetes. The primary outcome for this study is the development of diabetes. The study is expected to last a total of five years.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 2010
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 2004
Date type not reportedThis date has not been verified as actual or estimated.
June 30, 2005
Actual (reported)July 1, 2005
Actual (reported)January 2010
Actual (reported)January 2010
Actual (reported)Development of diabetes based on 1 positive OGTT or 2 fasting glucose levels
Dec 2009
Lipids, CBC, CRP, homocysteine, adiponectin, insulin, proinsulin, and routine biochemistry will be done annually
Dec2009
Avandamet \[ Rosuglitazone 2 and Metformin 500\]
\[Rosiglitazone 2mg/ Metformin 500mg\] twice daily
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
UWO Research Park
London, Ontario, N6G 4X8, Canada
Mount Sinai Hospital
Toronto, Ontario, M5G 1X5, Canada
Bernard Zinman, MD
MOUNT SINAI HOSPITAL
Stewart Harris, MD
Western University, Canada
207 participants (actual enrollment reported by the registry).
First Submitted
June 30, 2005
First Posted
July 1, 2005
Study Start
June 2004
Date type not reportedThis date has not been verified as actual or estimated.
The Effects of Exercise on Adipokine in Impaired Fasting Glucose or Impaired Glucose Tolerance Patients
Contact the study team to confirm eligibility.
Primary Completion
January 2010
Actual (reported)Study Completion
January 2010
Actual (reported)Last Updated
May 24, 2012
Record last verified: 2012-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: